Literature DB >> 27406829

Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients.

Mev Dominguez-Valentin1, Andrea Gras Navarro1, Aminur Mohummad Rahman1, Surendra Kumar2, Christèle Retière3, Elling Ulvestad4, Vessela Kristensen5, Morten Lund-Johansen6, Benedicte Alexandra Lie7, Per Øyvind Enger8, Gro Njølstad9, Einar Kristoffersen10, Stein Atle Lie11, Martha Chekenya12.   

Abstract

By affecting immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progression. In this study, we examined a hypothesized role for natural killer (NK) cells in impacting disease progression in this setting. We characterized 108 glioblastoma patients and 454 healthy controls for HLA-A,-B,-C, NK-cell KIR receptors, and CMV-specific antibodies and correlated these metrics with clinical parameters. Exome sequences from a large validation set of glioblastoma patients and control individuals were examined from in silico databases. We demonstrated that the KIR allele KIR2DS4*00101 was independently prognostic of prolonged survival. KIR2DS4*00101 displayed 100% concordance with cognate HLA-C1 ligands in glioblastoma patients, but not controls. In the context of both HLA-C1/C2 ligands for the KIR2DS4 receptor, patient survival was further extended. Notably, all patients carrying KIR2DS4*00101 alleles were CMV seropositive, but not control individuals, and exhibited increased NK-cell subpopulations, which expressed the cytotoxicity receptors CD16, NKG2D, and CD94/NKG2C. Finally, healthy controls exhibited a reduced risk for developing glioblastoma if they carried two KIR2DS4*00101 alleles, where protection was greatest among Caucasian individuals. Our findings suggest that KIR2DS4*00101 may offer a molecular biomarker to identify intrinsically milder forms of glioblastoma. Cancer Res; 76(18); 5326-36. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27406829     DOI: 10.1158/0008-5472.CAN-16-1162

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.

Authors:  Nicole A Wilski; Colby Stotesbury; Christina Del Casale; Brian Montoya; Eric Wong; Luis J Sigal; Christopher M Snyder
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

2.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

3.  Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.

Authors:  M Bahador; A Gras Navarro; M A Rahman; M Dominguez-Valentin; S Sarowar; E Ulvestad; G Njølstad; S A Lie; E K Kristoffersen; E Bratland; M Chekenya
Journal:  Oncoimmunology       Date:  2017-06-05       Impact factor: 8.110

Review 4.  The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer.

Authors:  Alexander James Sedgwick; Nazanin Ghazanfari; Patrick Constantinescu; Theo Mantamadiotis; Alexander David Barrow
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

5.  Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C.

Authors:  Malcolm J W Sim; Sumati Rajagopalan; Daniel M Altmann; Rosemary J Boyton; Peter D Sun; Eric O Long
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-28       Impact factor: 11.205

Review 6.  From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer.

Authors:  Nicole A Wilski; Christopher M Snyder
Journal:  Vaccines (Basel)       Date:  2019-07-09

7.  Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients.

Authors:  Dominik Lobinger; Jens Gempt; Wolfgang Sievert; Melanie Barz; Sven Schmitt; Huyen Thie Nguyen; Stefan Stangl; Caroline Werner; Fei Wang; Zhiyuan Wu; Hengyi Fan; Hannah Zanth; Maxim Shevtsov; Mathias Pilz; Isabelle Riederer; Melissa Schwab; Jürgen Schlegel; Gabriele Multhoff
Journal:  Front Mol Biosci       Date:  2021-05-17

Review 8.  CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.

Authors:  Michael C Burger; Congcong Zhang; Patrick N Harter; Annette Romanski; Florian Strassheimer; Christian Senft; Torsten Tonn; Joachim P Steinbach; Winfried S Wels
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

Review 9.  Recent Advances in Immune Cell Therapy for Glioblastoma.

Authors:  Xianhui Kang; Yiyang Zheng; Wandong Hong; Xixi Chen; Huiting Li; Baojun Huang; Zhenyang Huang; Hongli Tang; Wujun Geng
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

10.  Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer.

Authors:  Yongwen Luo; Liang Chen; Qiang Zhou; Yaoyi Xiong; Gang Wang; Xuefeng Liu; Yu Xiao; Lingao Ju; Xinghuan Wang
Journal:  J Cell Mol Med       Date:  2020-10-13       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.